NEW YORK, Jan. 18, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on ONVO, BEAT, BRKR, and DXCM which can be accessed for free by signing up to www.wallstequities.com/registration. On Wednesday, January 17, 2018, the NASDAQ Composite, the Dow
On Wednesday, shares in San Diego, California headquartered Organovo Holdings Inc. recorded a trading volume of 649,974 shares. The stock ended at $1.37, rising 0.74% from the last trading session. The stock is trading below its 50-day moving average by 5.60%. Furthermore, shares of Organovo, which designs and creates functional and 3D human tissues for use in medical research and therapeutic applications, have a Relative Strength Index (RSI) of 46.75. Get the full research report on ONVO for free by clicking below at: www.wallstequities.com/registration/?symbol=ONVO
Malvern, Pennsylvania headquartered BioTelemetry Inc.'s stock finished yesterday's session 1.52% higher at $33.40. A total volume of 454,603 shares was traded. The Company's shares have gained 14.97% in the last month and 53.21% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 17.91% and 7.29%, respectively. Furthermore, shares of BioTelemetry, which provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services, have an RSI of 69.11. Today's complimentary research report on BEAT is accessible at: www.wallstequities.com/registration/?symbol=BEAT
At the close of trading on Wednesday, shares in Billerica, Massachusetts headquartered Bruker Corp. saw a rise of 0.06%, ending the day at $34.22. The stock recorded a trading volume of 841,203 shares, which was higher than its three months average volume of 547.64 thousand shares. The Company's shares have advanced 10.60% in the previous three months and 50.88% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 0.08% and 16.53%, respectively. Moreover, shares of Bruker, which develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions worldwide, have an RSI of 48.31.
On January 05th, 2018, research firm BTIG Research initiated a 'Buy' rating on the Company's stock. Sign up for free on Wall St. Equities and claim the latest report on BRKR at: www.wallstequities.com/registration/?symbol=BRKR
San Diego, California headquartered DexCom Inc.'s shares ended the day 0.16% lower at $56.32 with a total trading volume of 1.26 million shares. The stock has gained 25.24% in the previous three months. The Company's shares are trading above their 50-day moving average by 1.30%. Additionally, shares of DexCom, which together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have an RSI of 50.65.
On January 04th, 2018, research firm Northland Capital downgraded the Company's stock rating from 'Market Perform' to 'Underperform'. See the free research coverage on DXCM at: www.wallstequities.com/registration/?symbol=DXCM
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/whats-happening-with-these-medical-research-stocks----organovo-biotelemetry-bruker-and-dexcom-300584468.html
SOURCE Morris Capital Inc
Subscribe to our Free Newsletters!
Birth Control Implant is a long-acting birth control contraceptive inserted into the arm. It is a ...
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...View All